Pr MD - Tiziana Life Member Board
| TLSA Stock | USD 0.95 0.03 3.26% |
Insider
Pr MD is Member Board of Tiziana Life Sciences
| Age | 67 |
| Address | 14/15 Conduit Street, London, United Kingdom, W1S 2XJ |
| Phone | 44 20 7495 2379 |
| Web | https://www.tizianalifesciences.com |
Tiziana Life Management Efficiency
The company has return on total asset (ROA) of (0.6958) % which means that it has lost $0.6958 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8123) %, meaning that it created substantial loss on money invested by shareholders. Tiziana Life's management efficiency ratios could be used to measure how well Tiziana Life manages its routine affairs as well as how well it operates its assets and liabilities. As of December 1, 2024, Return On Tangible Assets is expected to decline to -0.58. In addition to that, Return On Capital Employed is expected to decline to -0.89. At present, Tiziana Life's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 157 K, whereas Total Assets are forecasted to decline to about 10.9 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| DCPSA FFPM | Bionomics Ltd ADR | N/A | |
| Pr Little | Affimed NV | N/A | |
| Sandra Esq | Immunome | 51 | |
| Uwe Reusch | Affimed NV | N/A | |
| Andreas MD | Affimed NV | 63 | |
| Juli Miller | Adaptimmune Therapeutics Plc | N/A | |
| Wendy Blosser | Accustem Sciences | 57 | |
| BS CPA | Inhibrx | 42 | |
| Cynthia Sirard | Leap Therapeutics | 54 | |
| Alexander Fudukidis | Affimed NV | N/A | |
| Helen MBA | Adaptimmune Therapeutics Plc | 57 | |
| Joanna Brewer | Adaptimmune Therapeutics Plc | 48 | |
| David Mehalick | Coeptis Therapeutics | 55 | |
| Sbastien Desprez | Adaptimmune Therapeutics Plc | N/A | |
| Alan Esq | Corvus Pharmaceuticals | N/A | |
| Warren Volles | Biohaven Pharmaceutical Holding | N/A | |
| Dr DACVP | Biohaven Pharmaceutical Holding | 62 | |
| Adi ZuloffShani | Clearmind Medicine Common | 55 | |
| Corleen Roche | Immunome | 57 | |
| Gilad Babchuk | Clearmind Medicine Common | N/A | |
| Adi ZuloffShani | Scisparc | 55 | |
Management Performance
| Return On Equity | -1.81 | ||||
| Return On Asset | -0.7 |
Tiziana Life Sciences Leadership Team
Elected by the shareholders, the Tiziana Life's board of directors comprises two types of representatives: Tiziana Life inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Tiziana. The board's role is to monitor Tiziana Life's management team and ensure that shareholders' interests are well served. Tiziana Life's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Tiziana Life's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Richard Clarkson, Scientific Founder | ||
| Andrea Brancale, Scientific Founder | ||
| Gabriele MBA, Executive Founder | ||
| Keeren Shah, Chief Officer | ||
| RPh MD, Chief Officer | ||
| PharmD Clementi, Chief Officer | ||
| Pr Pellicciari, Consultant | ||
| MBA MBA, Ex Founder | ||
| Andrew Westwell, Scientific Founder | ||
| Napoleone MD, Member Board | ||
| Pr MD, Member Board |
Tiziana Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Tiziana Life a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.81 | ||||
| Return On Asset | -0.7 | ||||
| Current Valuation | 97.94 M | ||||
| Shares Outstanding | 103.82 M | ||||
| Shares Owned By Insiders | 35.56 % | ||||
| Shares Owned By Institutions | 1.76 % | ||||
| Number Of Shares Shorted | 274.93 K | ||||
| Price To Book | 53.31 X | ||||
| EBITDA | (15.79 M) | ||||
| Net Income | (17.24 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Tiziana Life Sciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Tiziana Life's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Tiziana Life Sciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Tiziana Life Sciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tiziana Life Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tiziana Life. If investors know Tiziana will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tiziana Life listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.13) | Revenue Per Share (0.02) | Return On Assets (0.70) | Return On Equity (1.81) |
The market value of Tiziana Life Sciences is measured differently than its book value, which is the value of Tiziana that is recorded on the company's balance sheet. Investors also form their own opinion of Tiziana Life's value that differs from its market value or its book value, called intrinsic value, which is Tiziana Life's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tiziana Life's market value can be influenced by many factors that don't directly affect Tiziana Life's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tiziana Life's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tiziana Life is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tiziana Life's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.